1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East & Africa Pulmonary Arterial Hypertension Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East & Africa Pulmonary Arterial Hypertension Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East & Africa Pulmonary Arterial Hypertension Market Regional Analysis
6.2 Middle East & Africa Pulmonary Arterial Hypertension Market Revenue 2020-2028 (US$ Million)
6.3 Middle East & Africa Pulmonary Arterial Hypertension Market Forecast Analysis
7. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis – by Drugs
7.1 Endothelin Receptor Antagonists
- 7.1.1 Overview
- 7.1.2 Endothelin Receptor Antagonists: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Prostacyclin and Prostacyclin Analogs
- 7.2.1 Overview
- 7.2.2 Prostacyclin and Prostacyclin Analogs: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 sGC Stimulators
- 7.3.1 Overview
- 7.3.2 sGC Stimulators: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.4 pde-5 Dipsticks
- 7.4.1 Overview
- 7.4.2 pde-5 Dipsticks: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
8. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis – by Type
8.1 Branded and Generics
- 8.1.1 Overview
- 8.1.2 Branded and Generics: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
9. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis – by Route of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.2 Intravenous/Subcutaneous
- 9.2.1 Overview
- 9.2.2 Intravenous/Subcutaneous: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.3 Inhalational
- 9.3.1 Overview
- 9.3.2 Inhalational: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
10. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies and Clinics
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies and Clinics: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.2 Online Pharmacies
- 10.2.1 Overview
- 10.2.2 Online Pharmacies: Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.3 Retail Pharmacies
- 10.3.1 Overview
- 10.3.2 Retail Pharmacies : Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast, 2020-2028 (US$ Million)
11. Middle East & Africa Pulmonary Arterial Hypertension Market – Middle East and Africa Analysis
11.1 Overview
11.2 Middle East and Africa
- 11.2.1 Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 11.2.1.1 Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 South Africa:
Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 South Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Drugs
- 11.2.1.1.2 South Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Type
- 11.2.1.1.3 South Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
- 11.2.1.1.4 South Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel
- 11.2.1.2 Saudi Arabia:
Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Saudi Arabia: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Drugs
- 11.2.1.2.2 Saudi Arabia: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Type
- 11.2.1.2.3 Saudi Arabia: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
- 11.2.1.2.4 Saudi Arabia: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel
- 11.2.1.3 UAE:
Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 UAE: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Drugs
- 11.2.1.3.2 UAE: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Type
- 11.2.1.3.3 UAE: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
- 11.2.1.3.4 UAE: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel
- 11.2.1.4 Rest of Middle East and Africa:
Middle East & Africa Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.4.1 Rest of Middle East and Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Drugs
- 11.2.1.4.2 Rest of Middle East and Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Type
- 11.2.1.4.3 Rest of Middle East and Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration
- 11.2.1.4.4 Rest of Middle East and Africa: Middle East & Africa Pulmonary Arterial Hypertension Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Bayer AG
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Gilead Sciences Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GSK Plc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Johnson & Johnson
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Lupin Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novartis AG
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Pfizer Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations